scorecardresearch
Add as a preferred source on Google
Thursday, April 16, 2026
TopicCovishield

Topic: Covishield

Death & the Covid vaccine: Why SC has directed govt to frame a ‘no-fault’ compensation scheme

SC was hearing pleas by grieving families who claimed their loved ones died due to adverse events linked to Covid vaccination. Govt denied direct link between vaccines & deaths.

Akhilesh’s claims about Covishield vaccine are baseless, says Union MoS for health SP Singh Baghel

SP chief has been raising alarm about Oxford-AstraZeneca vaccine, but Baghel points to WHO approval. Minister also confident of retaining his Agra seat, which is voting Tuesday.

How safe is AstraZeneca Covid vaccine & why there is no need to panic — some key questions answered

51 cases have been lodged in a UK court against biopharma company over claims that its Covid vaccine caused death and injury in several cases.

Don’t let anti-vaxxers weaponise AstraZeneca furore. Vaccines are safe—and we are the proof

Vaccines have eliminated two diseases—smallpox in humans and rinderpest in cattle. If they were killing one in 50,000 people, we wouldn’t be rolling them out across the globe for decades.

AstraZeneca vaccine safe, effective in kids, finds Lancet study. WHO still says for adults only

The vaccine, marketed as Covishield in India, induced antibody concentrations in children similar to those associated with high efficacy in adults, says study by UK researchers.

Didn’t suit global narrative that Indian firm could deliver quality, says SII’s Poonawalla

CEO of world’s largest vaccine maker says India is better equipped to deal with pandemics now, adds a global treaty is important to allow resource-sharing across borders.

‘No demand’: In Covishield’s home Pune, 1.41 lakh doses at private centres about to expire

Private hospitals in Pune municipal limits are staring at major vaccine wastage, blame free government drives and strict rules for booster eligibility and second dose gap.

Why you won’t get Covishield, Covaxin at a chemist yet, despite full market approval

Covishield and Covaxin have been fully authorised only for use in adults, and can only be used in a ‘programmatic setting’, which means you’ll still have to register on CoWin.

DCGI grants regular market approval to Covishield, Covaxin for use in adult population

Approval was granted under New Drugs & Clinical Trials Rules, 2019 citing conditions that Bharat Biotech & SII will submit clinical trials' data & vaccines will be supplied for programmatic setting.

Covishield, Covaxin prices may drop to Rs 275/dose after getting regular market approval

Bharat Biotech's Covaxin is currently priced at Rs 1,200 per dose while SII's Covishield costs Rs 780 at private facilities. Both the vaccines are only authorised for emergency use.

On Camera

Avalanche, enemy fire, and a strategy—how Indian Army took control of Siachen

The force for the operation was to be maintained by air through para drops by fixed wing aircrafts while the helicopter effort was primarily earmarked for tasks such as reconnaissance.

Russia raking in a windfall from Hormuz blockade. Export revenues doubled to $19 bn in March, says IEA

Despite damage to key Russian oil infrastructure by Ukrainian drone strikes in March, International Energy Agency data shows Russia’s earnings in March were highest for any month since January 2024.

Why Siliguri Corridor is strategically important for India & how it is being secured | Cut The Clutter

This special edition of Cut The Clutter, straight from the Siliguri corridor, details the strategic importance of the narrow strip of land in West Bengal, and how it’s a vital link connecting the Northeast to the rest of India.

The world’s in a flux. India must reform, consolidate & build a strong economy

We now live in a world order that will keep shifting. India must use this window. This also means we remain disciplined enough not to be knee-jerked into reacting to what Pakistan sees as its moment in the sun.